$ICPT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in INTERCEPT PHARMACEUTICALS, INC.. Get notifications about new insider transactions in INTERCEPT PHARMACEUTICALS, INC. for free.
Page: < prev 1 ... 2 3 4 5 6 7 8 9 10 ... 13 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 11 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 500 | 10,750 | 2,666 | 2.2 K to 2.7 K (+23.08 %) |
| Aug 24 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 9.82 | 865 | 8,496 | 3,894 | |
| Aug 24 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 9.82 | 109 | 1,071 | 0 | |
| Aug 24 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Sell | S | 206.85 | 974 | 201,472 | 962 | 1.9 K to 962 (-50.31 %) |
| Aug 24 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 9.82 | 865 | 8,496 | 1,936 | 1.1 K to 1.9 K (+80.77 %) |
| Aug 24 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 9.82 | 109 | 1,071 | 1,071 | 962 to 1.1 K (+11.33 %) |
| Aug 19 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 8.67 | 3,500 | 30,333 | 19,294 | |
| Aug 19 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 209.37 | 4,272 | 894,429 | 18,233 | 22.5 K to 18.2 K (-18.98 %) |
| Aug 19 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 8.67 | 3,500 | 30,333 | 22,505 | 19 K to 22.5 K (+18.42 %) |
| Aug 05 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 500 | 10,750 | 7,472 | |
| Aug 05 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 261.17 | 500 | 130,585 | 2,166 | 2.7 K to 2.2 K (-18.75 %) |
| Aug 05 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 500 | 10,750 | 2,666 | 2.2 K to 2.7 K (+23.08 %) |
| Aug 04 2015 | ICPT | INTERCEPT PHARMACE ... | McMinn Rachel | Chief Strategy Offi ... | Sell | S | 262.09 | 127 | 33,286 | 4,293 | 4.4 K to 4.3 K (-2.87 %) |
| Jul 24 2015 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 285.00 | 582 | 165,870 | 8,221 | 8.8 K to 8.2 K (-6.61 %) |
| Jul 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 9.82 | 973 | 9,557 | 109 | |
| Jul 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Sell | S | 279.01 | 973 | 271,477 | 962 | 1.9 K to 962 (-50.28 %) |
| Jul 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 9.82 | 973 | 9,557 | 1,935 | 962 to 1.9 K (+101.14 %) |
| Jul 21 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Grant | A | 0.00 | 285 | 0 | 1,120,609 | 1.1 M to 1.1 M (+0.03 %) |
| Jul 17 2015 | ICPT | INTERCEPT PHARMACE ... | McMinn Rachel | Chief Strategy Offi ... | Sell | S | 255.12 | 503 | 128,327 | 4,420 | 4.9 K to 4.4 K (-10.22 %) |
| Jul 14 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 12,500 | 108,334 | 116,628 | |
| Jul 14 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 250.00 | 12,500 | 3,125,000 | 507,014 | 519.5 K to 507 K (-2.41 %) |
| Jul 14 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 12,500 | 108,334 | 519,514 | 507 K to 519.5 K (+2.47 %) |
| Jul 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 21.50 | 4,000 | 86,000 | 2,923 | |
| Jul 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 8.67 | 67 | 581 | 0 | |
| Jul 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 243.69 | 130 | 31,680 | 10,709 | 10.8 K to 10.7 K (-1.20 %) |
| Jul 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 241.81 | 770 | 186,194 | 10,839 | 11.6 K to 10.8 K (-6.63 %) |
| Jul 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 241.57 | 1,000 | 241,571 | 11,609 | 12.6 K to 11.6 K (-7.93 %) |
| Jul 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 240.63 | 1,200 | 288,752 | 12,609 | 13.8 K to 12.6 K (-8.69 %) |
| Jul 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 238.64 | 367 | 87,580 | 13,809 | 14.2 K to 13.8 K (-2.59 %) |
| Jul 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 2,538.02 | 600 | 1,522,815 | 14,176 | 14.8 K to 14.2 K (-4.06 %) |
| Jul 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 21.50 | 4,000 | 86,000 | 14,776 | 10.8 K to 14.8 K (+37.12 %) |
| Jul 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 8.67 | 67 | 581 | 10,776 | 10.7 K to 10.8 K (+0.63 %) |
| Jul 07 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 0.00 | 1,623 | 0 | 3,245 | |
| Jul 07 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 239.00 | 41 | 9,799 | 19,005 | 19 K to 19 K (-0.22 %) |
| Jul 07 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 238.16 | 9 | 2,143 | 19,046 | 19.1 K to 19 K (-0.05 %) |
| Jul 07 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 236.13 | 801 | 189,140 | 19,055 | 19.9 K to 19.1 K (-4.03 %) |
| Jul 07 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 0.00 | 1,623 | 0 | 19,856 | 18.2 K to 19.9 K (+8.90 %) |
| Jul 07 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 0.00 | 649 | 0 | 1,298 | |
| Jul 07 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 0.00 | 649 | 0 | 10,709 | 10.1 K to 10.7 K (+6.45 %) |
| Jul 07 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 0.00 | 4,868 | 0 | 9,735 | |
| Jul 07 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 239.00 | 2 | 478 | 507,014 | 507 K to 507 K (0.00 %) |
| Jul 07 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 238.16 | 7 | 1,667 | 507,016 | 507 K to 507 K (0.00 %) |
| Jul 07 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 236.13 | 149 | 35,183 | 507,023 | 507.2 K to 507 K (-0.03 %) |
| Jul 07 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 0.00 | 4,868 | 0 | 507,172 | 502.3 K to 507.2 K (+0.97 %) |
| Jul 07 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 0.00 | 1,298 | 0 | 2,596 | |
| Jul 07 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 239.00 | 1 | 239 | 18,768 | 18.8 K to 18.8 K (-0.01 %) |
| Jul 07 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 238.16 | 2 | 476 | 18,769 | 18.8 K to 18.8 K (-0.01 %) |
| Jul 07 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 236.13 | 50 | 11,807 | 18,771 | 18.8 K to 18.8 K (-0.27 %) |
| Jul 07 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 0.00 | 1,298 | 0 | 18,821 | 17.5 K to 18.8 K (+7.41 %) |
| Jul 06 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 8.67 | 1,000 | 8,667 | 7,940 | |
| Jul 06 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 242.10 | 1,000 | 242,100 | 17,523 | 18.5 K to 17.5 K (-5.40 %) |
| Jul 06 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 8.67 | 1,000 | 8,667 | 18,523 | 17.5 K to 18.5 K (+5.71 %) |
| Jul 06 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 8.67 | 3,500 | 30,333 | 22,794 | |
| Jul 06 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 241.81 | 100 | 24,181 | 18,233 | 18.3 K to 18.2 K (-0.55 %) |
| Jul 06 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 240.59 | 381 | 91,664 | 18,333 | 18.7 K to 18.3 K (-2.04 %) |
| Jul 06 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 239.32 | 398 | 95,251 | 18,714 | 19.1 K to 18.7 K (-2.08 %) |
| Jul 06 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 238.51 | 1,902 | 453,641 | 19,112 | 21 K to 19.1 K (-9.05 %) |
| Jul 06 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 237.64 | 1,000 | 237,640 | 21,014 | 22 K to 21 K (-4.54 %) |
| Jul 06 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 8.67 | 3,500 | 30,333 | 22,014 | 18.5 K to 22 K (+18.90 %) |
| Jun 24 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 9.82 | 974 | 9,567 | 1,082 | |
| Jun 24 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Sell | S | 265.14 | 974 | 258,246 | 962 | 1.9 K to 962 (-50.31 %) |
| Jun 24 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 9.82 | 974 | 9,567 | 1,936 | 962 to 1.9 K (+101.25 %) |
| Jun 17 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 8.67 | 3,500 | 30,333 | 26,294 | |
| Jun 17 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 242.05 | 1,900 | 459,896 | 18,514 | 20.4 K to 18.5 K (-9.31 %) |
| Jun 17 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 241.03 | 1,600 | 385,650 | 20,414 | 22 K to 20.4 K (-7.27 %) |
| Jun 17 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 8.67 | 3,500 | 30,333 | 22,014 | 18.5 K to 22 K (+18.90 %) |
| Jun 12 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 391 | 8,407 | 7,972 | |
| Jun 12 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 238.21 | 391 | 93,140 | 2,166 | 2.6 K to 2.2 K (-15.29 %) |
| Jun 12 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 391 | 8,407 | 2,557 | 2.2 K to 2.6 K (+18.05 %) |
| Jun 10 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 8.67 | 4,000 | 34,667 | 67 | |
| Jun 10 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 250.34 | 2,000 | 500,670 | 10,060 | 12.1 K to 10.1 K (-16.58 %) |
| Jun 10 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 246.46 | 2,000 | 492,928 | 12,060 | 14.1 K to 12.1 K (-14.22 %) |
| Jun 10 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 8.67 | 4,000 | 34,667 | 14,060 | 10.1 K to 14.1 K (+39.76 %) |
| Jun 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 21.50 | 4,651 | 99,997 | 47,240 | |
| Jun 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 1,910 | 16,553 | 34,404 | |
| Jun 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 21.50 | 4,651 | 99,997 | 502,304 | 497.7 K to 502.3 K (+0.93 %) |
| Jun 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 1,910 | 16,553 | 497,653 | 495.7 K to 497.7 K (+0.39 %) |
| May 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 9.82 | 973 | 9,557 | 2,056 | |
| May 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Sell | S | 260.20 | 973 | 253,175 | 962 | 1.9 K to 962 (-50.28 %) |
| May 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 9.82 | 973 | 9,557 | 1,935 | 962 to 1.9 K (+101.14 %) |
| May 22 2015 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | M | 21.50 | 1,000 | 21,500 | 5,249 | |
| May 22 2015 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | M | 21.50 | 1,000 | 21,500 | 8,642 | 7.6 K to 8.6 K (+13.09 %) |
| May 19 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 8.67 | 3,500 | 30,333 | 29,794 | |
| May 19 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 307.60 | 1,984 | 610,274 | 18,514 | 20.5 K to 18.5 K (-9.68 %) |
| May 19 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 306.31 | 2,295 | 702,970 | 20,498 | 22.8 K to 20.5 K (-10.07 %) |
| May 19 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 8.67 | 3,500 | 30,333 | 22,793 | 19.3 K to 22.8 K (+18.14 %) |
| May 18 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 5,000 | 43,334 | 129,128 | |
| May 18 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 300.00 | 5,000 | 1,500,000 | 495,743 | 500.7 K to 495.7 K (-1.00 %) |
| May 18 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 5,000 | 43,334 | 500,743 | 495.7 K to 500.7 K (+1.01 %) |
| May 13 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 391 | 8,407 | 8,363 | |
| May 13 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 283.33 | 233 | 66,016 | 2,166 | 2.4 K to 2.2 K (-9.71 %) |
| May 13 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 272.79 | 158 | 43,101 | 2,399 | 2.6 K to 2.4 K (-6.18 %) |
| May 13 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 391 | 8,407 | 2,557 | 2.2 K to 2.6 K (+18.05 %) |
| May 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 8.67 | 4,000 | 34,667 | 0 | |
| May 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 262.00 | 200 | 52,400 | 10,060 | 10.3 K to 10.1 K (-1.95 %) |
| May 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 261.05 | 1,000 | 261,045 | 10,260 | 11.3 K to 10.3 K (-8.88 %) |
| May 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 260.00 | 1,000 | 260,000 | 11,260 | 12.3 K to 11.3 K (-8.16 %) |
| May 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 259.12 | 1,800 | 466,418 | 12,260 | 14.1 K to 12.3 K (-12.80 %) |
| May 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 8.67 | 4,000 | 34,667 | 14,060 | 10.1 K to 14.1 K (+39.76 %) |
| May 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 12,500 | 108,334 | 134,128 | |
| May 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 259.33 | 312 | 80,912 | 495,743 | 496.1 K to 495.7 K (-0.06 %) |
| May 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 258.50 | 400 | 103,400 | 496,055 | 496.5 K to 496.1 K (-0.08 %) |
| May 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 256.42 | 200 | 51,283 | 496,455 | 496.7 K to 496.5 K (-0.04 %) |
| May 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 255.49 | 661 | 168,881 | 496,655 | 497.3 K to 496.7 K (-0.13 %) |
| May 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 254.63 | 1,539 | 391,881 | 497,316 | 498.9 K to 497.3 K (-0.31 %) |
| May 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 253.53 | 4,338 | 1,099,791 | 498,855 | 503.2 K to 498.9 K (-0.86 %) |
| May 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 252.53 | 3,350 | 845,979 | 503,193 | 506.5 K to 503.2 K (-0.66 %) |
| May 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 251.39 | 1,700 | 427,368 | 506,543 | 508.2 K to 506.5 K (-0.33 %) |
| May 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 12,500 | 108,334 | 508,243 | 495.7 K to 508.2 K (+2.52 %) |
| Apr 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 9.82 | 974 | 9,567 | 3,029 | |
| Apr 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Sell | S | 278.50 | 974 | 271,259 | 962 | 1.9 K to 962 (-50.31 %) |
| Apr 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 9.82 | 974 | 9,567 | 1,936 | 962 to 1.9 K (+101.25 %) |
| Apr 14 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 391 | 8,407 | 8,754 | |
| Apr 14 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 272.10 | 391 | 106,391 | 2,166 | 2.6 K to 2.2 K (-15.29 %) |
| Apr 14 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 391 | 8,407 | 2,557 | 2.2 K to 2.6 K (+18.05 %) |
| Apr 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 8.67 | 4,000 | 34,667 | 4,000 | |
| Apr 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 271.64 | 2,000 | 543,280 | 10,060 | 12.1 K to 10.1 K (-16.58 %) |
| Apr 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 269.11 | 1,000 | 269,110 | 12,060 | 13.1 K to 12.1 K (-7.66 %) |
| Apr 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 266.18 | 1,000 | 266,180 | 13,060 | 14.1 K to 13.1 K (-7.11 %) |
| Apr 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 8.67 | 4,000 | 34,667 | 14,060 | 10.1 K to 14.1 K (+39.76 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 8.67 | 2,131 | 18,469 | 33,294 | |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 203 | 2,111 | 0 | |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 0.00 | 1,622 | 0 | 4,868 | |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 277.70 | 843 | 234,102 | 19,293 | 20.1 K to 19.3 K (-4.19 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 281.15 | 1,000 | 281,150 | 20,136 | 21.1 K to 20.1 K (-4.73 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 272.69 | 282 | 76,897 | 21,136 | 21.4 K to 21.1 K (-1.32 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 269.83 | 1,334 | 359,953 | 21,418 | 22.8 K to 21.4 K (-5.86 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 8.67 | 2,131 | 18,469 | 22,752 | 20.6 K to 22.8 K (+10.33 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 203 | 2,111 | 20,621 | 20.4 K to 20.6 K (+0.99 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 0.00 | 1,622 | 0 | 20,418 | 18.8 K to 20.4 K (+8.63 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 0.00 | 1,298 | 0 | 3,894 | |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 277.70 | 39 | 10,830 | 17,523 | 17.6 K to 17.5 K (-0.22 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 0.00 | 1,298 | 0 | 17,562 | 16.3 K to 17.6 K (+7.98 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 0.00 | 649 | 0 | 1,947 | |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 0.00 | 649 | 0 | 10,060 | 9.4 K to 10.1 K (+6.90 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 0.00 | 4,868 | 0 | 14,603 | |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 277.70 | 157 | 43,599 | 495,743 | 495.9 K to 495.7 K (-0.03 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 0.00 | 4,868 | 0 | 495,900 | 491 K to 495.9 K (+0.99 %) |
| Apr 01 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 293.34 | 300 | 88,001 | 16,264 | 16.6 K to 16.3 K (-1.81 %) |
| Apr 01 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 292.16 | 100 | 29,216 | 16,564 | 16.7 K to 16.6 K (-0.60 %) |
| Apr 01 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 291.00 | 100 | 29,100 | 16,664 | 16.8 K to 16.7 K (-0.60 %) |
| Apr 01 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 289.00 | 100 | 28,900 | 16,764 | 16.9 K to 16.8 K (-0.59 %) |
| Apr 01 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 288.00 | 100 | 28,800 | 16,864 | 17 K to 16.9 K (-0.59 %) |
| Apr 01 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 287.00 | 100 | 28,700 | 16,964 | 17.1 K to 17 K (-0.59 %) |
| Apr 01 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 286.00 | 100 | 28,600 | 17,064 | 17.2 K to 17.1 K (-0.58 %) |
| Apr 01 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 285.00 | 100 | 28,500 | 17,164 | 17.3 K to 17.2 K (-0.58 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 294.82 | 90 | 26,534 | 1,120,324 | 1.1 M to 1.1 M (-0.01 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 293.85 | 2,500 | 734,625 | 1,120,414 | 1.1 M to 1.1 M (-0.22 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 292.13 | 6,000 | 1,752,780 | 1,122,914 | 1.1 M to 1.1 M (-0.53 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 291.12 | 3,700 | 1,077,144 | 1,128,914 | 1.1 M to 1.1 M (-0.33 %) |